Medical devices, healthcare technology and the business of care
PMA approval · P150021

FREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM

Abbott Diabetes Care, Inc. · Decision date Sep 23, 2016

MEDTECHLEDGER EXPLANATIONP150021

What did the FDA approve?

FDA approved PMA P150021 on September 23, 2016, for the FreeStyle Libre Pro Flash Glucose Monitoring System from Abbott Diabetes Care, Inc. The approval covers a professional continuous glucose monitoring device for detecting trends and tracking patterns in adults 18 and older with diabetes. The system is intended for health care professionals, requires a prescription, and does not require user calibration with blood glucose values.

Sensor readings are made available to patients only through consultation with a health care professional. The statement describes the system as aiding detection of glucose excursions above or below the desired range to support therapy adjustments, with interpretation based on trends and patterns over time using available reports. The source does not include independent proof of safety or clinical effectiveness beyond this stated purpose.

FDA approval order statement

The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The System is intended for use by health care professionals and requires a prescription. Readings from the FreeStyle Libre Pro Sensor are only made available to patients through consultation with a health care professional. The System does not require user calibration with blood glucose values.The FreeStyle Libre Pro System aids in the detection of glucose level excursions above or below the desired range, facilitating therapy adjustments. Interpretation of the FreeStyle Libre Pro Flash Glucose Monitoring System readings should be based on the trends and patterns analyzed through time using the reports available.
Regulatory pathway
Original PMA
Clinical specialty
Clinical Chemistry
Decision date
Sep 23, 2016

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150021
Regulatory pathway
Premarket approval application
Product code
MDS
Decision code
APPR
Decision date
Sep 23, 2016
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sensor, glucose, invasive.

Product code
MDS
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P150021 received

    Application receipt date recorded by FDA.

  2. P150021 · FDA decision

    APPR

  3. P150021/S061 · Related supplement

    Freestyle Libre Pro Flash Glucose Monitoring System

Timeline entries are records held by MedtechLedger for P150021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150021

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Diabetes Care, Inc.PMA supplementSep 1, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Diabetes Care, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1360 S. Loop Rd., Alameda, CA, 94502

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records